Literature DB >> 18490056

Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma.

Nozomi Niitsu1, Masataka Okamoto, Hirokazu Nakamine, Masami Hirano.   

Abstract

We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18490056     DOI： 10.1016/j.leukres.2008.04.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  7 in total

1.  Magnetic resonance imaging of methotrexate-related lymphoproliferative disorder with a chief complaint of oral symptoms.

Authors:  Ami Kuribayashi; Sakurako Kawashima; Kou Kayamori; Junichiro Sakamoto; Hiroshi Tomisato; Hiroshi Watanabe; Tohru Kurabayashi
Journal:  Oral Radiol       Date:  2022-06-11       Impact factor: 1.852

2.  Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study.

Authors:  Hiroyuki Takahashi; Rika Sakai; Takayuki Sakuma; Ayako Matsumura; Kazuho Miyashita; Yoshimi Ishii; Yuki Nakajima; Ayumi Numata; Yukako Hattori; Takuya Miyazaki; Chizuko Hashimoto; Hideyuki Koharazawa; Sachiya Takemura; Jun Taguchi; Katsumichi Fujimaki; Hiroyuki Fujita; Hideaki Nakajima
Journal:  Indian J Hematol Blood Transfus       Date:  2020-06-23       Impact factor: 0.900

3.  Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes.

Authors:  Yao Sun; Monika Joks; Li-Ming Xu; Xiu-Li Chen; Dong Qian; Jin-Qiang You; Zhi-Yong Yuan
Journal:  Onco Targets Ther       Date:  2016-04-06       Impact factor: 4.147

4.  Lymphomatous Involvement of Male Breast in a Patient with Bilateral Gynecomastia: Demonstration with 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography.

Authors:  Punit Sharma
Journal:  Indian J Nucl Med       Date:  2017 Jul-Sep

5.  A Case of Primary Breast Diffuse Large B-Cell Lymphoma Treated with Chemotherapy Followed by Elective Field Radiation Therapy: A Brief Treatment Pattern Review from a Radiation Oncologist's Point of View.

Authors:  Kyu Chan Lee; Seung Heon Lee; KiHoon Sung; So Hyun Ahn; Jinho Choi; Seok Ho Lee; Jae Hoon Lee; Junshik Hong; Sang Hui Park
Journal:  Case Rep Oncol Med       Date:  2015-07-13

6.  Mutational profile of primary breast diffuse large B-cell lymphoma.

Authors:  Fernando Franco; Julia González-Rincón; Javier Lavernia; Juan F García; Paloma Martín; Carmen Bellas; Miguel A Piris; Lucia Pedrosa; José Miramón; José Gómez-Codina; Delvys Rodríguez-Abreu; Isidro Machado; Carmen Illueca; Jesús Alfaro; Mariano Provencio; Margarita Sánchez-Beato
Journal:  Oncotarget       Date:  2017-10-24

7.  Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.

Authors:  Shaoxuan Hu; Yuqin Song; Xiuhua Sun; Liping Su; Wei Zhang; Jing Jia; Ou Bai; Sheng Yang; Rong Liang; Xiaoling Li; Huilai Zhang; Yuhuan Gao; Weijing Zhang; Xiubin Xiao; Huizheng Bao; Ningju Wang; Hanyun Ren; Xinan Cen; Shun'e Yang; Yu Zhao; Yinan Wang; Yalan Wang; Aichun Liu; Jingwen Wang; Yuankai Shi; Ming Yuan; Yufu Li; Xiaohui He
Journal:  Cancer Sci       Date:  2018-11-11       Impact factor: 6.716
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.